Member Info for technick

That is terrible but may reflect multiple attempts by the lab to get a result from the sample... potentially... or just poor logistics for inconclusive results.

@flying both tests require RNA extraction to make the RNA available for the test chemistry. I think the difference is the speed of the Genedrive compared to lab instruments which typically take hours to do the same PCR cycling.

I think there may be more of an rns tomorrow or Friday to base interviews on? Only an opinion but would make sense.... maybe?

I think all good ceos keep an eye on sentiment

really good news, we need some firm news support as there is a solid product here

The Genedrive platform is it’s trump card

Coincided with the announcement that when they said they could do 50m tests a year they misspoke!

Ooo yes, lots of future opportunities for testing. MRSA, HAI, HPV, we’ve got the platform, we’ve got the sales, we’ve got the cash to develop new tests

FDA, other overseas territories, HCV, AIHL, DOD, TB

I think so Ben, I’ve seen it a few times and made me sit up thinking we’re off!

Omega has sales revenues of £4m and now a MC of £150m due to C19. Those sales revenues would be eclipsed by GDRs existing tests without their new C19 test so there has to be a bridging of the MC gap here shortly. Either of Onegas tests have been tested or have CE marks yet, GDRs has and is ready for sales...

I’ve put in an order for another 460k shares at lower than the ask, hoping that will get settled. Competition shouldn’t scare us, it shows there’s a market and the opportunity for acquisition is great...

I agree Sam, but to some extent that's why we are here and not where we should be, people are in for quick returns and don't base investment on anything other than bandwagon mentality. The ones who really benefit are the LTHs in my view. Personally I don't invest in more that 10 companies at a time and really try and research them. Otherwise it's slot machines.

Agree Jack, now we have product that os CE marked we will have sustained news around sales in the UK and EU, then further news around FDA and other territory sales, and then onto the POC development and launch later in the year. The company has focus, great products and proven diagnostics capability. A good year ahead!

ah yes hindsight investment, got to get me some of that, I'd be £Bns up ;p

My guess is ODX will not get there due to sensitivity, AVCT will get their with the mass spec partnership but will have limited market penetration due to equipment requirement for MS and specialist training etc, that GDR will get their test out for high throughput and by autumn will be there in POC for the second wave...

tripple sam, tripple ;)

check the detail at the back of the placing rns from the 5th May, full details in that

no, current share price reflective of waiting until placing shares are placed, I suspect this will continue rising from todays announcement and accelerate away on further commercial news. The product I believe is now launched

check the detail at the back of the placing rns from the 5th May, full details in that